Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. director reported a routine insider transaction involving deferred equity compensation. On 12/01/2025, the director acquired 1,451 Deferred Share Units (DSUs), each representing the right to receive one share of Kenvue common stock. These DSUs reflect deferral of cash fees under Kenvue’s Amended and Restated Deferred Fee Plan for Directors and are to be settled in shares after the director separates from service. Following this transaction, the director beneficially owned 35,906.289 DSUs, a figure that includes amounts accumulated through dividend reinvestment.
Kenvue Inc. Chief People Officer Luani Alvarado converted 2,020.7800 Restricted Stock Units into an equal number of common shares on December 1, 2025. 731.0000 shares were withheld at $17.2200 per share to pay taxes on the vesting. She now holds 32,649.14 common shares directly and 2,222.2800 RSUs, which vest in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026.
Kenvue Inc. insider updates holdings after equity award vesting. The company’s Chief Scientific Officer reported the vesting and settlement of 1,538.75 Restricted Stock Units into an equal number of Kenvue common shares on 12/01/2025 at an exercise price of $0, reflecting equity compensation rather than an open‑market purchase.
To cover taxes due at vesting, 788 common shares were withheld and disposed of at a price of $17.22 per share. Following these transactions, the officer directly holds 44,879.51 shares of Kenvue common stock and 1,538.86 RSUs, which include units acquired through dividend reinvestment and are scheduled to vest in installments subject to continued service through the vesting dates.
Kenvue Inc. (KVUE) reported insider equity activity by its Chief People Officer on 11/18/2025. Restricted stock units converted into common shares on a one-for-one basis, including 309 and 123 units that became common stock. A matching 309 and 123 shares were withheld to cover FICA taxes arising from the officer being retirement eligible.
After these transactions, the officer directly beneficially owned 31,359.36 shares of Kenvue common stock. The filing also notes remaining restricted stock unit awards of 8,384.47 and 12,622.07 units, which vest in three equal installments on 03/05/2025, 03/05/2026, 03/05/2027 and on 03/10/2026, 03/10/2027, 03/10/2028, respectively, subject to continued service.
Kenvue Inc. (KVUE) Chief Operations Officer reported routine equity compensation activity. On 11/18/2025, restricted stock units converted into 494 shares of common stock and a separate award converted into 166 shares, both on a one-for-one basis upon vesting. To cover FICA taxes related to retirement eligibility, 494 and 166 shares were withheld at a price of $14.37 per share.
After these transactions, the officer beneficially owned 64,441.23 shares of Kenvue common stock directly, along with 12,074.85 restricted stock units from one award and 15,485.69 restricted stock units from another. These RSU awards are scheduled to vest in three equal annual installments on specific dates in 2025, 2026, 2027, and 2028, subject to continued service.
Kenvue Inc. filed an initial ownership report for a senior executive showing no current holdings of company stock. The filing is a Form 3 for Kenvue Inc. (ticker KVUE) related to an event dated 11/17/2025.
The reporting person is identified as an officer of Kenvue, serving as Chief Digital & Marketing Officer, and is filing individually rather than as part of a group. In the accompanying ownership tables, the report states that no securities are beneficially owned, covering both non-derivative and derivative securities.
Kimberly-Clark Corporation filed a communication under Rule 425 describing a proposed transaction with Kenvue Inc. and the related shareholder approval process. Kimberly-Clark plans to file a registration statement on Form S-4 covering the proposed issuance of its common stock, which will include a joint proxy statement/prospectus to be mailed to both companies’ stockholders for votes on transaction-related proposals after SEC effectiveness. The communication emphasizes that it is not an offer to sell or buy securities and urges investors to read carefully the registration statement, joint proxy statement/prospectus, and related SEC filings when available. It also highlights that projections and other statements about expected benefits, synergies, financing, cash flow, and timing are forward-looking and subject to significant risks and uncertainties outlined in each company’s SEC reports.
Kenvue shared employee FAQs about its proposed transaction with Kimberly‑Clark, outlining how pay, benefits, time off, performance reviews, bonuses and long‑term incentives would be handled around closing. Equity awards will convert on a value‑for‑value basis: RSUs to Kimberly‑Clark RSUs, stock options to Kimberly‑Clark options with exercise price and count adjusted to maintain value, and PSUs to Kimberly‑Clark RSUs using the greater of actual or target performance (illustrated with a $10,000 example).
The FAQs state that eligible employees involuntarily terminated before closing receive severance under their current plan, and those terminated on or after closing and before the first anniversary receive the better of Kenvue’s or Kimberly‑Clark’s plan. The communication also notes that Kimberly‑Clark will file a Form S‑4 with a joint proxy statement/prospectus to be mailed after SEC effectiveness.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a passive stake in Kenvue Inc. (KVUE). The firm beneficially owns 115,533,086 shares of common stock, representing 6.0% of the class as of the event date 09/30/2025.
The filer reports 110,837,001 shares with sole voting power and 115,243,402 shares with sole dispositive power, with zero shared voting or dispositive power. The reporting person is classified as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Kimberly-Clark Corporation has issued a communication describing a proposed transaction with Kenvue Inc., in which the two companies plan to combine to create what they describe as a preeminent global health and wellness leader. The message comes from a senior Kimberly-Clark executive, who characterizes this as one of the most important days in the company’s history and highlights the strategic significance of joining two iconic American brands.
The companies plan to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus, and will seek stockholder approval from both Kimberly-Clark and Kenvue investors. The communication emphasizes that investors should rely on the full registration statement and joint proxy statement/prospectus when available, and it provides standard cautionary language that forward-looking statements about expected benefits, synergies, and financial impact are subject to numerous risks, including regulatory approvals, integration challenges, transaction timing, market reactions, and broader economic and operational uncertainties.